Application Note 147: Variations in the Binding Kinetics of Native and Recombinant Protein Receptors
The long and arduous process of drug development involves screening of drug candidates by determining their affinities towards a cellular target and the kinetics of the interactions. A variety of …
Application Note 145: KINETIC MEASUREMENTS OF COVID-19 VIRAL S1 PROTEIN WITH CELLULAR AND RECOMBINANT ACE2 RECEPTORS
The pandemic due to the SARS-CoV-2 continues to evolve and remains an international concern. Covid infection is caused by the air-borne coronavirus 2 (SARS-CoV-2) and its mutants. The viral invasion …
Application Note 144: Single Cell Apoptosis Monitoring with SPRm Impedance
lectrochemical impedance spectroscopy (EIS) technique consists in introducing a perturbation into the sample by means of an AC voltage to an electrode and detecting its current response.
Application Note 143: Monitoring Electrochemical Activities of Single Prussian Blue Nanoparticles with SPRm Electrochemistry
Prussian blue is a pigment that is used to color paints, inks, textiles, and other commercial product. Prussian blue nanoparticles (PBNPs) are nanomaterials that present unique properties and excellent biocompatibility: they can be synthesized in mild conditions and can be derivatized with polymers and/or biomolecules. In addition, with its ability to transfer electrons efficiently and its large redox potential between reduction and oxidation, these nanoparticles result in enzyme-like characteristics which is ideal for biomedicine as therapy and diagnostic agents.
Application Note 142: Small Molecule Binding to Membrane Transporter Using SPRm200
Transporters are large proteins (40–200 kDa) located in the plasma membrane of cells and organelles. They normally span the membrane many times and modulate the transfer of xenobiotics (including nutrients, micronutrients and pharmaceuticals), and endogenous substances such as neurotransmitters, hormones, signaling molecules, vitamins across cellular membranes, tissues or organ barriers.
Application Note 141: SPRM Measurements of Binding Kinetics between Rituximab and CD20 on Live B Cells
Cell-based immunotherapy has gained great attention from researchers and pharmaceutical companies, particularly due to its promise to treat various cancers. Understanding the interaction between drug candidates and targets on the cell membrane is crucial to drug development.
Application Note 140: Membrane Transport Protein Binding Kinetics Using Label-Free SPRm200
In this application note, binding interactions of an antibody to a membrane transport receptor were studied using SPRm 200. Transporters have important roles in physiological processes ranging from cellular uptake of nutrients to the absorption of drugs. Despite their importance as a drug discovery, it is difficult to determine its function: direct biophysical studies require these proteins be solubilized and purified and between their extraction and reconstitution, transport activity cannot be measured because of the lack of a vectorial environment.
Application Note 139: Single-Injection Kinetic Measurement Technique for Studies of COVID-19 S1 Protein and ACE2 Binding
This application note shows the application of the single-injection measurement technique in binding kinetic studies between COVID-19 S1 and ACE2 proteins. The five-channel SPR instrument, with the BI-DirectFlow™ technology, provides a unique multi-channel technique for precise sample delivery and high-quality measurement.
Application Note 138: Kinetic Measurement of COVID-19 S1 Protein and ACE2 Binding
The coronavirus 2019 (COVID-19) pandemic continues to evolve. This disease is caused by the highly contagious coronavirus 2 (SARS-CoV-2) and is initiated by the viral invasion into host cells through viral attachment to angiotensin (Ang)-converting enzyme 2 (ACE2). ACE2, expressed in numerous different tissues, is the receptor through which the COVID-19 spike-protein (S-protein) gains entry into cells for subsequent viral replication.
Application Note 137: Ginnalin A and Tabersonine Inhibition of Amyloid β(1-42) Aggregation
Alzheimer’s disease (AD) is currently ranked as the sixth leading cause of death in the United States and is the most common neurological disorder. Production and accumulation of amyloid-beta (Aβ) peptides in the brain are a hallmark of AD. Among Aβ peptides of different lengths, Αβ(1-42) has the highest propensity to aggregate.